BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well ...

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,Stefan Irion ,Mark Kotter ,University Of Cambridge ,Linkedin ,Bayer Ag ,National Resilience ,Twitter ,Verition Fund ,Facebook ,Bluerock Therapeutics ,Chief Scientific Officer ,Private Securities Litigation Reform Act ,Versant Ventures ,Gene Therapy ,March Ventures ,Foresite Capital ,Milky Way ,Charles River Laboratories ,